Not long after his birth in 2013, Paul Siebenthal‘s son Noah was diagnosed with cystic fibrosis (CF) and the new father became aware that his son would struggle with a chronic, life-threatening disease for his entire life. However, Paul Siebenthal did not accept that there is currently no cure for the…
Peter and Mary Frey are a young couple just like any other, starting a family together. However, there is one thing that makes their family different from the average American household. Mary suffers from cystic fibrosis (CF), a genetic and chronic disease that causes the excessive production of mucus in the lungs,…
The 2015 UK Cystic Fibrosis Conference (UKCFC), the United Kingdom’s most-anticipated annual conference for the cystic fibrosis community that brings together esteemed disease experts, researchers, health professionals, patients and family members, is set to take place on September 22-23, 2015. The two-day event is expected to attract over 300 attendees to Manchester, UK for…
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary disease using its patented iSPERSE™ (inhaled small particles easily respirable and emitted) technology, has just announced it will be presenting preclinical data on the pharmacokinetics and potency of PUR1900 during the upcoming 2015 North American Cystic Fibrosis Conference. PUR1900 is an…
Earlier this week, AbbVie launched the voting contest portion of its yearly AbbVie CF Scholarship program. Everyone in the CF advocacy community and beyond is encouraged to visit www.AbbVieCFScholarship.com today through September 22, 2015 to weigh in on who best deserves this year’s Thriving Undergraduate or Graduate Scholar title and…
While the majority of patients diagnosed with cystic fibrosis (CF) at birth experience the symptoms of the disease during their childhood, Larry Brian is an uncommon case. The 25-year old patient never really understood the extent of suffering from the chronic and debilitating disease until he went to college.
Proteostasis Therapeutics, Inc. (PTI), a biotechnology company working on breakthrough therapeutics to treat diseases caused by defects in protein processing, recently announced that it has secured new financing worth $37 million, which will be dedicated to further developing its primary product candidate for cystic fibrosis for testing in human clinical studies. Cystic fibrosis…
The first-of-its kind Kitabis Pak, a co-packaged generic tobramycin inhalation solution and PARI LC PLUS Nebulizer indicated for cystic fibrosis, was recently named one of 2014’s 10 notable drug-device approvals. The list is currently published in this month’s issue of Drug Development & Delivery. The Kitabis…
Raptor Pharmaceutical Corp., recently announced it has reached an agreement with Tripex Pharmaceuticals over the rights to Quinsair, a first-of-its-kind inhaled fluoroquinolone indicated for chronic respiratory infections caused by Psuedomonas aeruginosa in adult cystic fibrosis patients. Quinsair was granted marketing authorization by the European Commission and Health Canada earlier this year.
Global biotechnology company and Cystic Fibrosis therapeutic leader Vertex, together with the University of Massachusetts (UMass), recently revealed the awardees of the yearly Vertex Science Leaders Scholarship, which will fund 4 years of their education in any Science, Technology, Engineering and Math (STEM) course at any UMass campus. This scholarship is part…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.